Immuneering Corporation IMRX

Company Overview

Immuneering Corporation is a clinical-stage biotechnology company focused on developing targeted oncology therapeutics. The company operates within the biopharmaceutical and precision oncology industries, with a strategic emphasis on improving treatment outcomes for patients with genetically defined cancers. Immuneering’s core approach centers on rational drug design informed by systems biology and computational modeling to overcome limitations of existing targeted cancer therapies.

The company’s primary revenue drivers are its proprietary oncology drug candidates, which are currently in clinical and preclinical development rather than commercial sales. Immuneering is best known for its work targeting the MAPK and mTOR signaling pathways, which are frequently dysregulated in solid tumors. Founded in 2008, Immuneering initially focused on systems biology applications before evolving into a drug development company and subsequently becoming publicly traded following its initial public offering in 2021.